CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1

Simple Summary Melanoma is one of the most aggressive skin cancers, characterized by metastasis to the lymph nodes and a high capacity to develop drug resistance. There is a lack of knowledge on the mechanisms contributing to lymphatic vessel formation and metastasis regulation in malignant melanoma. We previously reported the involvement of CD147, a transmembrane glycoprotein overexpressed in melanoma, in the regulation of the tumor microenvironment and angiogenesis. The aim of our study was to further determine how CD147 is involved in lymphangiogenesis regulation. Our results revealed that high CD147 expression is correlated with the number of lymphatic vessels in the human melanoma lymph nodes and that paracrine CD147 upregulates lymphangiogenesis through lymphangiogenic mediators in vitro and in vivo, suggesting that CD147 could be a promising target for melanoma-associated lymphangiogenesis inhibition. Abstract Malignant melanoma is one of the most aggressive skin cancers and is characterized by early lymph node metastasis and the capacity to develop resistance to therapies. Hence, understanding the regulation of lymphangiogenesis through mechanisms contributing to lymphatic vessel formation represents a treatment strategy for metastatic cancer. We have previously shown that CD147, a transmembrane glycoprotein overexpressed in melanoma, regulates the angiogenic process in endothelial cells. In this study, we show a correlation between high CD147 expression levels and the number of lymphatic vessels expressing LYVE-1, Podoplanin, and VEGFR-3 in human melanoma lymph nodes. CD147 upregulates in vitro lymphangiogenesis and its related mediators through the PROX-1 transcription factor. In vivo studies in a melanoma model confirmed that CD147 is involved in metastasis through a similar mechanism as in vitro. This study, demonstrating the paracrine role of CD147 in the lymphangiogenesis process, suggests that CD147 could be a promising target for the inhibition of melanoma-associated lymphangiogenesis.

[1]  A. Ziemys,et al.  Dissecting the Lymphatic System to Predict Melanoma Metastasis , 2020, Frontiers in Oncology.

[2]  M. Erić,et al.  Survival prediction in patients with cutaneous melanoma by tumour lymphangiogenesis , 2020, Acta clinica Belgica.

[3]  Tingting Qin,et al.  Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling , 2020, Cancer biology & medicine.

[4]  S. Morrison,et al.  Lymph protects metastasizing melanoma cells from ferroptosis , 2020, Nature.

[5]  Dennis Jones.  Parallels of Resistance between Angiogenesis and Lymphangiogenesis Inhibition in Cancer Therapy , 2020, Cells.

[6]  Lixiu Xu,et al.  CD147 promotes cervical cancer migration and invasion by up-regulating fatty acid synthase expression. , 2019, International journal of clinical and experimental pathology.

[7]  C. Lebbé,et al.  CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker , 2019, Cancers.

[8]  A. Hartmann,et al.  Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma , 2019, Molecular oncology.

[9]  I. Rosas,et al.  Glycogen synthase kinase 3-β inhibition induces lymphangiogenesis through β-catenin-dependent and mTOR-independent pathways , 2019, PloS one.

[10]  J. Wilting,et al.  Non-canonical WNT-signaling controls differentiation of lymphatics and extension lymphangiogenesis via RAC and JNK signaling , 2019, Scientific Reports.

[11]  Ming Yan,et al.  CD147 promotes progression of head and neck squamous cell carcinoma via NF‐kappa B signaling , 2018, Journal of cellular and molecular medicine.

[12]  Ying Cheng,et al.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial , 2018, JAMA oncology.

[13]  Y. Kakeji,et al.  PROX1 Is Associated with Cancer Progression and Prognosis in Gastric Cancer , 2018, AntiCancer Research.

[14]  D. Azar,et al.  Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies—A review , 2018, Medicinal research reviews.

[15]  Y. Lin,et al.  Overexpression of EMMPRIN is associated with lymph node metastasis and advanced stage of non-small cell lung cancer: a retrospective study , 2017, BMC Pulmonary Medicine.

[16]  K. Ishikawa,et al.  CD147 expression correlates with lymph node metastasis in T1-T2 squamous cell carcinoma of the tongue , 2017, Oncology letters.

[17]  M. Shin,et al.  Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels. , 2016, Biochemical and biophysical research communications.

[18]  M. Saif,et al.  Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer , 2016, Cancer Chemotherapy and Pharmacology.

[19]  L. French,et al.  Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages , 2016, Scientific Reports.

[20]  M. Hsu,et al.  Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells , 2016, PloS one.

[21]  C. Lebbé,et al.  EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma , 2016, Experimental dermatology.

[22]  M. Detmar,et al.  Tumor lymphangiogenesis and new drug development. , 2016, Advanced drug delivery reviews.

[23]  P. Angus,et al.  Circulating CD147 predicts mortality in advanced hepatocellular carcinoma , 2016, Journal of gastroenterology and hepatology.

[24]  K. Friedrich,et al.  Soluble extracellular matrix metalloproteinase inducer (EMMPRIN, EMN) regulates cancer‐related cellular functions by homotypic interactions with surface CD147 , 2015, The FEBS journal.

[25]  G. G. Van den Eynden,et al.  Peritumoral D2‐40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma , 2015, Journal of cutaneous pathology.

[26]  T. Oyama,et al.  Nuclear PROX1 is Associated with Hypoxia-Inducible Factor 1α Expression and Cancer Progression in Esophageal Squamous Cell Carcinoma , 2015, Annals of Surgical Oncology.

[27]  L. Perez-Cano,et al.  EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF , 2015, Oncotarget.

[28]  C. Scharf,et al.  Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN , 2014, Journal of molecular cell biology.

[29]  M. Hsu,et al.  Src contributes to IL6-induced vascular endothelial growth factor-C expression in lymphatic endothelial cells , 2014, Angiogenesis.

[30]  R. Derynck,et al.  BMP-9 balances endothelial cell fate , 2013, Proceedings of the National Academy of Sciences.

[31]  M. Pan,et al.  Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9 , 2012, Clinical Cancer Research.

[32]  F. Passarelli,et al.  Expression of vascular endothelial growth factor‐C in primary cutaneous melanoma predicts sentinel lymph node positivity , 2012, Journal of cutaneous pathology.

[33]  Xi-qing Sun,et al.  Effects of Simulated Microgravity on Human Umbilical Vein Endothelial Cell Angiogenesis and Role of the PI3K-Akt-eNOS Signal Pathway , 2012, PloS one.

[34]  M. Lindström,et al.  Transcription factor PROX1: its role in development and cancer , 2012, Cancer and Metastasis Reviews.

[35]  K. Opeskin,et al.  Vascular Endothelial Growth Factor Receptor-3 Directly Interacts with Phosphatidylinositol 3-Kinase to Regulate Lymphangiogenesis , 2012, PloS one.

[36]  Michael Detmar,et al.  Lymphangiogenesis and cancer. , 2011, Genes & cancer.

[37]  G. Christofori,et al.  Molecular mechanisms of lymphangiogenesis in development and cancer. , 2011, The International journal of developmental biology.

[38]  Jay W. Shin,et al.  Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. , 2010, The American journal of pathology.

[39]  G. Millot,et al.  EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. , 2009, Blood.

[40]  Zhihai Ma,et al.  Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis , 2009, Journal of cutaneous pathology.

[41]  D. Khayat,et al.  Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. , 2009, European journal of cancer.

[42]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[43]  D. Ruiter,et al.  Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice , 2007, International journal of cancer.

[44]  D. Bates,et al.  Chemokine-mediated migration of melanoma cells towards lymphatics – a mechanism contributing to metastasis , 2007, Oncogene.

[45]  K. Alitalo,et al.  VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. , 2007, Blood.

[46]  C. Bokemeyer,et al.  Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis , 2007, Clinical Cancer Research.

[47]  T. Isobe,et al.  Membrane Type 1 Matrix Metalloproteinase (MT1-MMP/MMP-14) Cleaves and Releases a 22-kDa Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Fragment from Tumor Cells* , 2006, Journal of Biological Chemistry.

[48]  G. Sauter,et al.  High incidence of EMMPRIN expression in human tumors , 2006, International journal of cancer.

[49]  Yi Tang,et al.  Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. , 2005, Cancer research.

[50]  M. Herlyn,et al.  Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. , 2004, The Journal of investigative dermatology.

[51]  J. Lavail,et al.  The microvesicle as a vehicle for EMMPRIN in tumor–stromal interactions , 2004, Oncogene.

[52]  Michael Detmar,et al.  Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. , 2003, The American journal of pathology.

[53]  K. Alitalo,et al.  Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox‐1 homeobox transcription factor , 2002, The EMBO journal.

[54]  S. Stacker,et al.  The role of tumor lymphangiogenesis in metastatic spread , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  K. Alitalo,et al.  Vascular growth factors and lymphangiogenesis. , 2002, Physiological reviews.

[56]  D. Ferguson,et al.  Mouse LYVE-1 Is an Endocytic Receptor for Hyaluronan in Lymphatic Endothelium* , 2001, The Journal of Biological Chemistry.

[57]  P. Wesseling,et al.  The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin αvβ3 expression , 2001 .

[58]  C. Turner.  Paxillin and focal adhesion signalling , 2000, Nature Cell Biology.

[59]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[60]  G. Oliver,et al.  Prox1 Function Is Required for the Development of the Murine Lymphatic System , 1999, Cell.

[61]  E. Tschachler,et al.  Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. , 1999, The American journal of pathology.

[62]  H. Guo,et al.  The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. , 1995, Cancer research.

[63]  C. Figdor,et al.  Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice , 1991, Clinical & Experimental Metastasis.

[64]  S. Mourah,et al.  Cell membrane vesicles as a tool for the study of direct epithelial-stromal interaction: lessons from CD147. , 2013, Methods in molecular biology.

[65]  D. Ribatti.  Antiangiogenic therapy accelerates tumor metastasis. , 2011, Leukemia research.

[66]  F. Calvo,et al.  Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. , 2005, The American journal of pathology.

[67]  H. Kowalski,et al.  [Podoplanin--a specific marker for lymphatic endothelium expressed in angiosarcoma]. , 1999, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[68]  B. Giovanella,et al.  Exceptional lethality for nude mice of cells derived from a primary human melanoma. , 1985, Cancer research.

[69]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.